Mr. Fu Xiaocong | Molecular Biology | Best Innovation Award

Shanghai Paisi Xin Biopharmaceutical Technology Co., Ltd. Malaysia

Dr. Xiaocong Fu is a highly accomplished Senior Tumor Immunology Researcher with more than a decade of experience in the development of cell therapy and gene/nucleic acid-based therapeutics. Currently based in Shanghai, he holds a PhD and has served in both academic and industrial roles, including as Founder of PSM Biotech and Associate Professor at Taylor’s University. His career encompasses a broad range of translational research activities with a strong focus on clinical immunology, drug mechanism validation, and precision oncology. He has published over 30 academic papers, with 13 as the first author in SCI-indexed journals, and holds more than nine personal invention patents. Dr. Fu is certified in GCP, CAP auditing, and biosafety regulations, with additional advisory roles in AI research and biotechnology projects. His multifaceted expertise includes immune function analysis, CAR-T/TCR-T method development, and organoid model systems, all of which reflect his dedication to innovation and real-world impact. His unique ability to combine clinical relevance with scientific discovery positions him as a leading figure in the field of tumor immunology and a strong candidate for prestigious innovation and research awards.

Professional Profile

• ORCID Profile

Education

Dr. Xiaocong Fu holds a Doctorate in Tumor Immunology, which has laid the scientific foundation for his highly specialized career in immunotherapy research. In addition to his academic training in immunology, he pursued advanced studies in business and innovation management at the China Europe International Business School, equipping him with a strategic understanding of biotech commercialization and research leadership. This interdisciplinary educational background has uniquely positioned him to integrate laboratory innovation with real-world therapeutic applications. His formal training includes rigorous technical and regulatory coursework, exemplified by certifications in Good Clinical Practice (GCP) and clinical trial quality management. Dr. Fu has also completed specialized training in biosafety and laboratory quality systems, including certification from the Shanghai Biosafety Training and Assessment Program and the College of American Pathologists (CAP). These credentials have enabled him to oversee clinical laboratory standards and contribute to high-stakes regulatory audits and clinical research. His academic affiliation with Taylor’s University as an Associate Professor further demonstrates his commitment to continuous learning, academic mentorship, and scientific excellence. The combination of scientific rigor and managerial insight distinguishes Dr. Fu’s educational journey and reflects his preparedness to drive complex, multidisciplinary projects in immunology and therapeutic development.

Professional Experience

Dr. Xiaocong Fu’s professional journey spans more than a decade of progressive responsibility in both industry and academia, reflecting a strong blend of translational research and entrepreneurial leadership. From 2012 to 2019, he worked at Shanghai WuXi AppTec Co., Ltd., where he played a critical role in preclinical and clinical immunology research. His responsibilities included the development of orthotopic tumor models, pharmacokinetic/pharmacodynamic studies, immune function assays, and clinical biomarker validation. During this time, he built expertise in flow cytometry, immune subpopulation analysis, and organoid construction platforms. As Technical Director of the CAP Clinical Center, Dr. Fu successfully developed and validated multiple clinical methods, including those for CAR-T therapies and phosphorylation-related biomarker detection. His current roles include Founder of PSM Biotech, where he leads innovation in cell and gene therapy platforms, and Associate Professor at Taylor’s University, where he contributes to academic research and mentorship. He also serves as Vice President of the Jiangxi Chamber of Commerce and holds advisory roles with AI research institutes. Dr. Fu’s professional scope covers scientific innovation, quality control, clinical trial management, and biotech entrepreneurship, establishing him as a multifaceted leader in the biomedical and pharmaceutical research sectors.

Research Interests

Dr. Xiaocong Fu’s research interests lie at the forefront of tumor immunology, cell therapy development, and translational clinical science. His primary focus is on understanding the mechanisms of immune response in cancer, particularly through the development and validation of CAR-T and TCR-T therapies. He is deeply involved in immune-mediated killing analyses, including ADCC (antibody-dependent cellular cytotoxicity), CDC (complement-dependent cytotoxicity), ADCP (antibody-dependent cellular phagocytosis), and TLR (toll-like receptor) functions. Dr. Fu also explores immune phenotyping and biomarker discovery, especially in relation to hematological malignancies and solid tumors. Another key area of interest is the use of induced pluripotent stem cells (iPSCs) for disease modeling and drug response simulation, with his team constructing organoid platforms for more precise in vitro analyses. Additionally, he is passionate about integrating gene editing technologies such as CRISPR to develop immune cell-based models that mimic in vivo responses. Dr. Fu’s interests extend to clinical pharmacology, biomarker-based patient stratification, and receptor occupancy studies, all aimed at creating more effective, personalized therapeutic strategies. His research is inherently translational, bridging the gap between laboratory innovation and clinical application to improve patient outcomes in cancer immunotherapy.

Research Skills

Dr. Xiaocong Fu possesses a wide array of advanced research skills that make him a standout contributor in the field of tumor immunology and clinical translational research. He is proficient in both in vitro and in vivo assays, including the development of orthotopic tumor models and functional immune assays. He has mastered multiparameter flow cytometry and is capable of operating high-throughput cytometry instruments such as the BD Fortessa X-20 and Canto systems, applying panels with up to 18 colors. His skill set includes the quantitative analysis of intracellular and extracellular signaling molecules, using detection platforms like Cytometric Bead Array (CBA) and Meso Scale Discovery (MSD). Dr. Fu is experienced in gene editing using CRISPR/Cas9 technologies, having successfully developed monoclonal iPSCs with precise gene knock-ins/knockouts. In clinical pharmacology, he has validated several PK/PD methods for CAR-T therapies and phosphorylation biomarkers. His technical leadership extends to immunophenotyping of both lymphoid and myeloid subpopulations, receptor occupancy assays, and biomarker tracking. He is also adept at clinical laboratory quality systems, having contributed to CAP audits and biosafety program implementations. These diverse, high-level research skills have enabled him to lead multidisciplinary projects across discovery, validation, and clinical translation domains.

Awards and Honors

Throughout his career, Dr. Xiaocong Fu has received numerous accolades that highlight his commitment to excellence and innovation in biomedical research. While specific award titles are not listed in the provided profile, his recognition can be inferred from his leadership roles and scientific achievements. His appointment as an Associate Professor at Taylor’s University, a position typically awarded to individuals with significant academic contributions, underscores his research credibility. His selection as a CAP auditor and a GCP-certified clinical trial manager reflects the high level of trust regulatory and research bodies place in his judgment and technical competence. As the Founder of PSM Biotech, he has also been acknowledged for his entrepreneurial efforts in translating immunological science into therapeutic platforms. Moreover, his advisory role in AI-based scientific projects further demonstrates peer recognition of his interdisciplinary expertise. With over 13 first-author SCI publications and nine personal invention patents, Dr. Fu’s body of work stands as a testament to sustained scholarly and innovative output. These milestones serve as informal yet powerful recognitions of his contributions, suggesting that he is not only a subject matter expert but also a recognized leader in his field.

Conclusion

Dr. Xiaocong Fu exemplifies the fusion of scientific excellence, clinical relevance, and innovative thinking necessary to transform cancer therapy through immune system modulation. His rich educational background, expansive professional experience, and cutting-edge research portfolio position him at the forefront of biomedical innovation. From pioneering CAR-T and TCR-T therapies to constructing iPSC-based organoid models, his work covers the full spectrum of research from basic science to translational application. As a skilled researcher, technical leader, and biotech entrepreneur, Dr. Fu has developed and validated multiple clinical methodologies, driven discovery in tumor immunology, and fostered collaborations across academia, industry, and regulatory agencies. His research consistently addresses real-world challenges in oncology and immunotherapy, leveraging both molecular precision and systems-level insight. Although there is room to expand his visibility in global academic networks and enhance commercialization outcomes, Dr. Fu’s existing contributions are both impactful and future-focused. He is a model candidate for honors such as the Best Innovation Award in Research and represents the caliber of researcher who not only advances knowledge but also changes lives through science.